Surrogate approaches in development of monoclonal antibodies

Drug Discovery Today

Volumn 14, Issue 23-24, 2009, Pages 1159-1165

  Bornstein, Gadi Gazit ^a   Klakamp, Scott L ^b   Andrews, Laura ^c   Boyle, William J ^d   Tabrizi, Mohammad ^d  

^a ASTRAZENECA   (United Kingdom)

^b Takeda San Francisco   (United States)

^c GENZYME CORPORATION   (United States)

^d AnaptysBio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TGN 1412;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; BIOPHYSICS; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CROSS REACTION; CYTOKINE STORM; DISEASE MODEL; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOLECULAR GENETICS; MOLECULAR INTERACTION; MOUSE STRAIN; NONHUMAN; PHARMACODYNAMICS; REVIEW; SPECIES DIFFERENCE; STIMULUS RESPONSE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CROSS REACTIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULIN ISOTYPES; RECEPTORS, FC; RESEARCH DESIGN; TRANSLATIONAL RESEARCH;

EID: 71749093472     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.09.014     Document Type: Review

References (69)

1. Tabrizi M.A., et al. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov. Today 14 (2009) 298-305
2. Buckley L.A., et al. Nonclinical aspects of biopharmaceuticl development: discussion of case studies at a PhRMA-FDA workshop. Int. J. Toxicol. 27 (2008) 303-312
3. Tabrizi M.A., and Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12 (2007) 540-547
4. Tabrizi M.A., and Roskos L.K. Exposure-response relationships for therapeutic biologic products. In: Meibohem B. (Ed). Pharmacokinetics and Pharmacodynamics of Biotech Drugs (2006), Wiley 295-327
5. Tabrizi M.A., et al. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11 (2006) 81-88
6. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20 (2008) 460-470
7. Raghavan M., and Bjorkman P.J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12 (1996) 181-220
8. Zhou J., et al. Generation of mutated variants of the human form of the MHC class I-related receptor. FcRn, with increased affinity for mouse immunoglobulin. J. Mol. Biol. 332 (2003) 901-913
9. Ivan E., and Colovai A.I. Human Fc receptors: critical targets in the treatment of autoimmune diseases and transplant rejections. Hum. Immunol. 67 (2006) 479-491
10. Shields R.L., et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276 (2001) 6591-6604
11. Ober R.J., et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13 (2001) 1551-1559
12. Dall'Acqua W.F., et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169 (2002) 5171-5180
13. Dall'Acqua W.F., et al. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281 (2006) 23514-23524
14. Raghavan M., et al. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34 (1995) 14649-14657
15. Kim J.K., et al. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur. J. Immunol. 24 (1994) 2429-2434
16. Medesan C., et al. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol. 158 (1997) 2217-2221
17. Medesan C., et al. Comparative studies of the rat IgG to further delineate the Fc:FcRn interaction site. Eur. J. Immunol. 28 (1998) 2092-2100
18. Fossati-Jimack L., et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J. Exp. Med. 191 (2000) 1293-1302
19. Duncan A.R., and Winter G. The binding site for C1q on IgG. Nature 332 (1988) 738-740
20. Schumaker V.N., et al. Ultracentrifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 15 (1976) 5175-5181
21. Bruggemann M., et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166 (1987) 1351-1361
22. Riechmann L., et al. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
23. Desjarlais J.R., et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Disc. Today 12 (2007) 898-910
24. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19 (2001) 275-290
25. Nimmerjahn F., and Ravetch J.V. Fcγ receptors: old friends and new family members. Immunity 24 (2006) 19-28
26. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
27. Ahmad A., and Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 10 (1996) 258-266
28. Mandelboim O., et al. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5640-5644
29. Mechetina L.V., et al. Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII. Immunogenetics 54 (2002) 463-468
30. Nimmerjahn F., et al. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
31. Hamaguchi Y., et al. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (2006) 743-753
32. Rogers K.A., et al. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177 (2006) 3848-3856
33. Isaacs J.D., et al. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J. Immunol. 161 (1998) 3862-3869
34. Steplewski Z., et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4852-4856
35. Lutterbuese P., et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol. Immunother. 56 (2007) 459-468
36. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
37. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
38. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26 (2008) 1789-1796
39. Naundorf S., et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int. J. Cancer 100 (2002) 101-110
40. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, July 1997. Retrieved from http://www.ich.org
41. Wellendorph P., et al. No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions. J. Mol. Endocrinol. 42 (2009) 215-223
42. Lee G.-S. Phenotype of a calbindin-D9k gene knockout is compensated for by the induction of other calcium transporter genes in a mouse model. J. Bone Miner. Res. 22 (2007) 1968-1978
43. Koch P.J., et al. Lessons from loricrin-deficient mice: compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein. J. Cell Biol. 151 (2000) 389-400
44. Tanabe M., et al. Compensatory response of IL-1 gene knockout mice after pulmonary infection with Klebsiella pneumoniae. J. Med. Microbiol. 54 (2005) 7-13
45. Inoue T. Concept of a 'relevant animal model'. In: D'Arcy P.F., and Harron D.W.G. (Eds). Proceedings of The Fourth International Conference on Harmonization Brussels 1997. The Queen's University at Belfast (1998) 209-219
46. Bugelski P.J., et al. Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum. Exp. Toxicol. 19 (2000) 230-243
47. Kostenuik P.J., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res. 24 (2009) 182-195
48. Bekker P.J., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19 (2004) 1059-1066
49. Lacey D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
50. Thoma-Uszynski S., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 291 (2001) 1544-1547
51. Veninga H., et al. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J. Immunol. 181 (2008) 6574-6583
52. Hirano E., et al. Functional rescue of elastin insufficiency in mice by the human elastin gene: implications for mouse models of human disease. Circ. Res. 101 (2007) 523-531
53. Locksley R.M., et al. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann. Inst. Pasteur Immunol. 138 (1987) 744-749
54. Gessner A., et al. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 189 (1993) 419-435
55. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
56. Expert scientific group on phase-one clinical trias 2006 Retrieved from www.dh.gov.uk
57. Waibler Z., et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 3 (2008) e1708
58. Nguyen D.H., et al. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7765-7770
59. Tabrizi, M.A. and Suria, H. (2009) Application of translational biomarkers in development of antibody-based therapeutics. Drug Disc., 5(1).
60. Kenakin T. Stimulus-response mechanisms. In: Weissman G. (Ed). Pharmacologic Analysis of Drug-Receptor Interaction (1993), Raven Press 39-68
61. Goldberg N.D. Cyclic-nucleotides and cell function. In: Weissman G. (Ed). Cell Membranes, Biochemistry, Cell biology and Pathology (1975), H.P. Publishing 185-202
62. Kufer P., et al. A revival of bispecific antibodies. Trends Biotechnol. 22 (2004) 238-244
63. Shields R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
64. Yamane-Ohnuki N., and Satoh M. Production of therapeutic antibodies with controlled fucosylation. mAbs 1 (2009) 230-236
65. D'Argouges S., et al. Combination of rituximab and blinatumomab (MT103, MEDI-538), a T cell-engaging CD19/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk. Res. 33 (2008) 465-473
66. Bostrom J., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323 (2009) 1610-1614
67. ®: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11 (2009) 22-30
68. Bargou R., et al. Tumor regression in cancer patients by very low doses of a T cell engaging antibody. Science 321 (2008) 974-977
69. ® antibody MEDI-538 (MT103/Blinatumomab) delivered subcutaneously in animal models. AACR, #2131. Retrieved from http://www.micromet.de/fileadmin/template/main/pdf/download/AACR_2008_MEDI-538_SC_Poster_Final.pdf